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ABSTRACT
The genetic mechanisms underlying disease progression, relapse and therapy 
resistance in mantle cell lymphoma (MCL) remain largely unknown. Whole-exome 
sequencing was performed in 27 MCL samples from 13 patients, representing the 
largest analyzed series of consecutive biopsies obtained at diagnosis and/or relapse for 
this type of lymphoma. Eighteen genes were found to be recurrently mutated in these 
samples, including known (ATM, MEF2B and MLL2) and novel mutation targets (S1PR1 
and CARD11). CARD11, a scaffold protein required for B-cell receptor (BCR)-induced 
NF-κB activation, was subsequently screened in an additional 173 MCL samples and 
mutations were observed in 5.5% of cases. Based on in vitro cell line-based experiments, 
overexpression of CARD11 mutants were demonstrated to confer resistance to the BCR-
inhibitor ibrutinib and NF-κB-inhibitor lenalidomide. Genetic alterations acquired in 
the relapse samples were found to be largely non-recurrent, in line with the branched 
evolutionary pattern of clonal evolution observed in most cases. In summary, this study 
highlights the genetic heterogeneity in MCL, in particular at relapse, and provides for 
the first time genetic evidence of BCR/NF-κB activation in a subset of MCL.
INTRODUCTION
Mantle cell lymphoma (MCL) is a mature B-cell 
neoplasm that constitutes 5–7% of all lymphomas. MCL 
was considered to arise from naive B-cells that populate 
the mantle zone of lymphoid follicles, but recent findings 
advocate that antigen-experienced B-cells can also give 
rise to MCL [1–4]. Two main morphological subtypes 
of MCL, classical and blastoid, have been described and 
the latter is associated with a particularly poor prognosis 
for patients [5]. Clinically, most of the MCL cases show 
an aggressive disease course, with a limited duration of 
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response to conventional chemotherapy and frequent 
relapses, resulting in an overall short survival time as 
compared to other B-cell lymphomas [6]. 
The initial oncogenic event in MCL, in the vast 
majority of cases, is a t(11;14)(q13;q32) translocation that 
juxtaposes the CCND1 gene, encoding cyclin D1, to the 
immunoglobulin heavy chain (IGH) locus [7]. Mutations 
and/or deletions in the gene encoding ATM, a key 
regulator of the DNA damage-response machinery, have 
been identified in up to 50% of MCL cases and constitute 
one of the major secondary genetic events in MCL 
development [8]. Genetic alterations affecting other DNA 
damage response factors, including CHEK2 and P53, have 
also been described [9, 10]. Furthermore, TNFAIP3 (A20), 
encoding a negative regulator of the NF-κB pathway, is 
frequently deleted in MCL [11]. 
Recently, a number of next-generation sequencing-
based approaches have led to the discovery of novel 
oncogenic mechanisms in several types of mature B-cell 
lymphomas, including diffuse large B-cell lymphoma 
(DLBCL) [12–17], follicular lymphoma [18] and Burkitt 
lymphoma [19]. In MCL, RNA-sequencing revealed 
frequent mutations in NOTCH1, which were found to 
be associated with poor clinical outcomes [20]. Targeted 
re- sequencing of 18 genes further showed that UBR5, 
an E3 ubiquitin ligase-encoding gene, was mutated in 
18% of the MCL samples analyzed [21]. Recently, two 
whole-genome and/or whole-exome sequencing (WES) 
studies on 29 and 56 MCL cases, respectively, identified 
additional mutated genes, including those encoding 
chromatin modifiers (WHSC1, MLL2, MLL3, MEF2B 
and SMARCA4), a cell adhesion factor (FAT4), cell cycle 
regulators (SMC1A and POT1), an anti-apoptotic factor 
(BIRC3) and NOTCH2 [22, 23]. 
As the clinical course of MCL patients is variable, 
and the genetic landscape of tumors might be quite 
heterogeneous, sequencing of additional tumor genomes 
can provide further insight on deregulated pathways that 
are involved in this disease. Furthermore, the genetic 
mechanisms linked to relapse and therapy resistance, are still 
largely unknown. To this end, we compared the mutation 
landscape of a set of primary (at diagnosis) and relapse 
MCL tumors samples derived from the same patients.
RESULTS 
The landscape of mutations in the coding 
genome of primary and relapse MCL
WES was performed on 27 tumors (11 primary and 
16 relapse) and 8 matched non-tumor- samples derived 
from 13 MCL patients (Figure 1A and Table S1). Together, 
a mean sequence depth greater than 76x was achieved 
and on average, 88.0% (range, 81.1–94.3%) of bases 
constituting the human coding genome were covered by 
at least 10 sequencing reads (Table S2). 
An overview of data analysis strategy is shown in 
Figure S1. Somatic (tumor-specific) mutation analysis was 
first performed in 16 tumors (7 primary and 9 relapse) for 
which paired non-tumor control samples were available 
(Figure S1, green shadow). Altogether, 274 somatic, non-
synonymous variants were identified in 254 genes. From 
these, 56 and 105 variants were specific for primary or 
relapse samples, respectively, whereas 113 variants were 
shared between primary and relapse samples (Figure 1B, 
left panel, “with non-tumor control”; Table S3). 
Variants presented only in the primary or relapse 
samples were subsequently determined in 11 tumors 
(4 primary and 7 relapse) for which the respective non-
tumor control samples were not available (Figure S1, 
blue shadow). Nineteen non-synonymous SNVs were 
specifically identified in the primary samples and 
83 non- synonymous SNVs as well as 6 indels were only 
observed in relapse cases (Table S3). These alterations 
were considered as of likely somatic origin since germline 
variants are expected to be present in all tumor samples, 
except in case of loss of genetic material. Additional 
somatic variants in these tumors, including 94 SNVs and 
7 indels, were identified by filtering the mutations that 
are shared by the paired primary and relapse samples 
(Table S4; Figure S1, pink shadow). To exclude mutations 
with potential germline origin, only variants associated 
with previously reported, recurrently mutated genes in 
MCL and DLBCL [12–14, 20–24] and with minor allele 
frequency < 0.1% in 1000 genome were considered. 
Altogether, 209 of potentially somatic variants were 
observed in 194 genes in the 11 tumors samples without 
paired non-tumor controls (Figure1B, right panel). 
Recurrently mutated genes in MCLs
By joining all analysis for tumor-related 
variants, 454 non-silent SNVs and 29 indels, somatic 
or putatively somatic, were identified in the 27 MCL 
samples. Twenty-five recurrent mutation targets, i.e. 
genes affected by non-silent SNVs and indels in at 
least two patients, were identified (Table S5). Seven 
genes (TTN, FAT1, PKHD1, PCLO, FLG, ABBA13 and 
DNAH5) that are highly mutated/damaged in germline 
genome from healthy individuals at a population level 
were subsequently excluded [25], and the remaining 
18 genes are nominated as recurrently mutated genes 
for this patient cohort (Figure 1C). Except for ATM, 
MEF2B and MLL2, these genes may represent novel 
mutation targets in MCL. S1PR1 was found mutated 
in four tumor samples derived from two patients. It 
encodes for the sphingosine-1-phosphate receptor 1, 
which has been shown expressed in mantle zone B cells 
and MCL [26, 27]. Mutations in the CARD11 gene, 
which is known to be recurrently targeted in DLBCL 
and in splenic marginal zone lymphomas [28, 29], were 
discovered in three tumor samples derived from two 
patients. A mutation in the CARD11 gene has previously 
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been described in 1/29 primary MCL cases [22], but to 
the best of our knowledge, recurrent mutations in the 
CARD11 gene have not been reported in MCL cell line 
or MCL cases in the literature. Importantly, however, 
our re-analysis of exome data from the aforementioned 
studies uncovered a limited number of mutations 
affecting S1PR1 in each cohort. In the first cohort [23], 
one patient harbored a frameshift deletion and in the 
second cohort [22], one patient harbored a missense 
mutation (R324L) and a second mutation harbored an 
in-frame insertion (G122_S123insN). Two patients with 
CARD11 mutations were also observed in the second 
cohort (P100Q and K215T). Other recurrent mutation 
targets that have been implicated in different types of 
cancers included PPM1D and GON4L (Table S5).
CARD11 mutations in MCLs
Due to the known importance of activating 
mutations in the coiled-coil (CC) domain of the CARD11 
protein in the pathobiology of DLBCL, the observation of 
mutations in our analysis of two published cohorts [28, 30] 
and in a third unpublished exome cohort of unrelated 
Canadian MCL samples, this gene domain was further 
screened by Sanger sequencing in an extended cohort of 
MCL. Altogether, 5.5% (11/200) of MCL samples or 5.6% 
(10/179) of the MCL patients were affected by mutations 
in the CC domain of CARD11 (Figure 2A and Table S6), 
including the mutations identified by WES (in P5 and P9, 
Table S6). The mutation frequency in CARD11 in our 
MCL cohort is thus about half as that observed in previous 
Figure 1: Clinical timelines and landscape of somatic mutations in mantle cell lymphoma (MCL) patients. (A) Sample 
information with disease event timelines for the thirteen MCL cases included in the WES study. (B) Number of somatic, non-silent variants 
identified in each MCL tumor sample (blue, only detected in the primary tumor; red, only detected in the relapse tumor; gray, shared by 
paired primary and relapse MCL). P, primary tumors; R, relapse tumors. (C) Recurrently mutated genes in 13 patients with MCL. Genes are 
listed only when they were affected by non-silent SNVs or indels in at least two MCL patients. #, additional missense SNVs were observed 
in the marked sample. 
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described DLBCL cohorts [13, 28]. Notably, some of the 
mutations identified in MCL samples are identical to 
those observed in DLBCL, including G123S, K215M 
and D230N. The mutations status in our cohort was not 
associated with any of the morphological subtypes and did 
not affect the overall survival of patients (Table S7). But 
notably, CARD11 mutations tended to be more frequent 
in relapse tumors, although not to a significant degree 
(36.4% (4/11) at relapse vs. 22.9% (43/188) in primary 
MCL, p = 0.2190, Table S7). 
Activating mutations in the CC domain of CARD11 
may result in a constitutive activation of B-cell receptor 
(BCR)/NF-κB signaling and render the mutant cells 
resistant or sensitive to some of the BCR/NF-κB inhibitors 
(targeting molecules upstream or downstream of CARD11, 
respectively) [28]. Six MCL cell lines (Granta519, JVM2, 
Rec-1, Mino, Jeko-1 and Z-138) were characterized by 
WES to identify CARD11 mutations or related mutations 
and were also tested in vitro by treatment with ibrutinib 
(a BTK inhibitor) and/or lenalidomide (a NF-κB inhibitor). 
The proliferation of four MCL cell lines (Rec-1, Mino, 
Z-138 and Jeko-1) was inhibited to various degrees 
by either ibrutinib or lenalidomide or by combination 
of two drugs (Figure 2 and Figure S2). Although no 
CARD11 mutations were found in any of the 6 MCL lines 
sequenced, other mutations affecting the BCR or NF-κB 
pathway might explain the observed treatment responses 
(Table S8). For instance, i) a damaging mutation in 
NFKBIB was identified in the cell line Rec-1, which was 
sensitive to both drugs, especially lenalidomide (Table S8), 
and ii) a nonsense mutation in the gene encoding TRAF2, a 
factor involved in the non-canonical NF-κB pathway, was 
found in Z-138, which might result in ibrutinib resistance 
[31], but at the same time did not affect sensitivity to 
lenalidomide (Table S8 and Figure S2). 
Wild-type and four CARD11 mutants (G123S, 
D230N, D357E and Y361C) were subsequently 
overexpressed in the ibrutinib/lenalidomide-sensitive 
cell line Rec-1 and insensitive cell lines Granta519 and 
JVM2. The expression level of wild-type CARD11 and 
its different mutants was monitored by western blot 
analysis (Figure S3), and the transfection efficiency was 
estimated by expression of GFP. CARD11 mutants, but not 
the wild-type protein, desensitize the Rec-1 cell line to 
ibrutinib and lenalidomide treatment, and the difference 
is significant especially when the D357E mutant was 
introduced and the combination of ibrutinib/lenalidomide 
with higher concentrations were introduced (Figure 2B). 
The other two MCL cell lines (JVM2 and Granta519) 
remained insensitive to both drugs (Figure S4). These two 
cell lines are positive for Epstein-Barr virus (EBV), an 
activator of the alternative NF-κB pathway, and therefore, 
may render the cells resistant to BCR/NF-κB pathway 
inhibitors. Taken together, acquiring CARD11 mutations 
might result in resistance to inhibitors targeting the BCR/
NF-κB signaling pathway.
Genetic alterations associated with tumor 
relapse are heterogeneous
Altogether, 194 somatic alterations were specifically 
identified in the relapse samples, including 183 non-
synonymous SNVs and 11 indels (Figure S1 and Table S3B). 
Thus, a median of 12 variants (range, 0–40) per case 
has been acquired in the relapse MCL samples. These 
mutations however, are largely non-recurrent, with only 
one gene, PPM1D, involved in p53 signaling, mutated in 
two relapse samples (P3-R1 and P6-R). Affected genes 
were subsequently assigned to pathways with WebGestalt 
analysis [32] and KEGG [33], and the MAPK, p53 and ErbB 
signaling pathways were shown to be enriched for genes 
affected by mutations in the relapse samples (Figure S5 and 
Table S9). By performing literature mining, we furthermore 
identified that DNA repair, NF-κB and Wnt signaling 
pathways might also be associated with genetic lesions 
present at relapse (Figure S5). 
Clonal evolution in different MCL paired tumors
In order to determine whether tumors collected at 
different time points from the same patient were clonally 
related, the coding junctions of IGHV-IGHD-IGHJ 
rearrangements in altogether 25 tumor samples from 
11 patients were amplified. V gene sub-families including 
IGHV3 and IGHV4 were preferentially used as previously 
reported [34]. The dominant tumor cell clones, based on 
the V(D)J coding joints, were identical in paired samples 
from the same individual in all patients, suggesting that 
common precursor for the primary and relapsed tumors 
(Table S10). The IGHV genes were unmutated/minimally 
mutated in most of the samples, except in a few cases 
(P1- P, P5-P and P5-R, Table S10).
Tumor clonal evolution may occur through a 
branched or a linear model [35]. Based on the number of 
non-silent SNVs and indels that were specific or shared 
between the paired tumor samples, the history of clonal 
evolution in each sample was further inferred. In most 
of cases (P1-P9), unique genetic lesions were observed 
in both the primary and relapse MCL samples, and this 
scenario is consistent with a predominantly branched 
evolutionary model (P1-P9 in Figure 3A). For example, 
a mutation in ATM (p.G2063E) was observed in P7-P but 
not in P7-R (Figure 1C), conversely PLCG1 was mutated 
only in P7-R. Nevertheless, in two cases, all lesions 
identified in the primary samples were maintained in the 
relapse tumors (P10 and P11), which is consistent with 
a linear pattern of evolution (P10-P11 in Figure 3A). 
The copy number changes estimated by the WES data in 
general support the above findings.
The composition of base substitutions was further 
analyzed for primary and relapsed samples with matched 
non-tumor controls. For this analysis, all somatic 
mutations including silent mutations as well as mutations 
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Figure 2: Variants identified in CARD11 gene resulted in resistance to ibrutinib and lenalidomide treatments. (A) The 
distribution of CARD11 variants identified in the discovery and the expanded cohorts of MCL patients. Altogether, 200 Swedish MCL 
samples from 179 patients were screened by WES and/or Sanger sequencing. The screening effort was focused on the coiled-coil domain 
of CARD11 (from exon 4 to exon 8). The positions of variants in coiled-coil domain of CARD11 are indicated by arrowheads. One mutation 
(p.K215M) was found in two samples of P5. (B) Drug inhibition assay in MCL cell lines with over expression of wild-type or the mutant 
forms of CARD11 with adenovirus system. The MCL cell line Rec-1 was treated with lenalidomide, ibrutinib or with a combination of the 
two drugs for four days at the concentrations indicated. The average percentages of viable cells from four independent experiments were 
plotted and the error bars indicate the standard errors. The difference is significant for mutant D357E vs. wild-type (p = 0.04921), when 
treated with ibrutinib (5 nM); mutant D357E vs. wild-type or GFP control (p = 0.02058 and 0.02057), when treated with lenalidomide 
(20 μM); mutant D357E vs. wild-type (p = 0.02419) when treated with ibrutinib (5 nM) and lenalidomide (20 μM) (paired-sample sign test).
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in the non-coding regions were included. Mutation 
patterns were altered in the relapse samples as compared 
to the corresponding primary samples in three patients 
(P6, P7 and P9), but only to a statistically significant level 
in P6 (p = 0.0355, Wilcoxon signed-rank test, Figure 3B). 
Interestingly, all three patients had been treated with 
autologous stem cell transplantation (ASCT) (Table S1). 
As the primary and relapse tumors in these three patients 
shared the same V(D)J sequences, like the other patients, 
this may suggest that although the relapse tumor is 
likely derived from the same precursors/stem cells as the 
primary tumor, the transplantation procedure might lead 
Figure 3: Clonal evolution of MCL based on mutational analyses. (A) Clonal evolution of relapse samples analyzed based on 
analysis of non-silent mutations. Arrows indicate the clonal pathway between samples. In each case, the analyzed primary MCL tumor is 
represented by an orange cell, the relapse tumor by a pink cell, and second relapse tumor by a dark-pink cell (available in P3 and P8-P10), 
and third relapse tumor by a brown cell (P10). The non-tumor control samples are represented as green cells and inferred clones are shown 
as blue cells. The number of genetic lesions acquired in the progression of MCL is depicted. The numbers with double quotation marks 
indicate that these shared mutations were achieved by filtering with mutations described in previous literature on DLBCL and MCL (see 
Materials and Methods). The time interval between primary and relapse or between the two relapses was indicated as number of months (m) 
beside the dotted line. Asterisks (for P3 and P10) indicate that the primary sample is not included in this study. (B) The pattern of somatic 
mutations identified in each primary and relapsed MCL tumors with paired non-tumor controls. Samples derived from the same patients 
were subgrouped. Mutation types that significantly differ in a given relapse sample as compared to the corresponding primary sample 
(or the first relapse sample if primary sample is not available) is labeled with asterisk. Wilcoxon signed-rank test was used for statistical 
analysis. ns, not significant; *p < 0.05.
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to selection of a different sub-clone of precursor cells or 
influence the pattern of mutations acquired at the later 
stage. 
DISCUSSION 
MCL is treated with front-line combination 
chemotherapy or intensive chemo-immunotherapy 
followed by stem-cell transplantation as consolidation [6]. 
Most of the patients initially respond to these therapies, 
but tumor relapse invariably occurs and the disease 
remains incurable. In this study, WES was performed in 
paired primary and relapsed MCL tumors and genetic 
changes associated with therapy resistance and disease 
relapse were identified. 
The genomic alterations at diagnosis and 
progression have so far only been studied in two MCL 
cases by NGS, showing linear or branched pattern of 
clonal evolution, respectively [22]. In our study, with 11 
cases studied, a branched evolutionary pattern was most 
prevalent. Furthermore, we discovered that MCL relapse 
tumors acquire on average 12 genetic lesions. However, 
these lesions are very heterogeneous, and most often non-
recurrent, suggesting that multiple/different mechanisms 
might be involved in disease progression and this may 
contribute to the difficulties in obtaining long-lasting 
remissions in MCL patients. Moreover, specific therapy 
might also affect the clonal evolution patterns observed at 
relapse. For instance patients treated with ASCT had the 
most diverged primary/relapse clones. Our study, although 
by far the largest NGS analysis on paired primary/relapse 
samples, suggests that a substantially higher number 
of cases will be required in order to identify potential 
recurrent genetic events that are associated with disease 
relapse. 
CARD11, a scaffold protein that forms a complex 
with BCL10 and MALT1 [36], is required for antigen 
receptor-induced NF-κB activation in B- and T-cells [28]. 
The expression of MALT1 but not BCL10 increased when 
several mutations in CARD11 were expressed in MCL 
cell lines (data not shown). Gain-of-function mutations in 
CARD11 have been associated with lymphomas including 
DLBCLs and marginal zone lymphomas [28, 30]. In this 
study, recurrent mutations were observed in the coiled-coil 
domain of CARD11 in MCL, providing genetic evidence 
for a pathogenic role of the chronic activation of BCR/NF-
κB signaling in these tumors. Ibrutinib, a BTK inhibitor, 
has shown encouraging anti-tumor activity against various 
B-cell malignancies including MCL [37]. However, as 
CARD11 is located downstream of BTK in the signaling 
cascade, ibrutinib may not have an effect on MCL cases 
that carry CARD11 mutations. Lenalidomide, a drug that 
alone, or in combination with ibrutinib, can inhibit the 
growth of ABC-DLBCL cell lines by downregulating 
transcription factors IRF4 and SPIB, which in turn 
amplify the NF-κB activity [38], also showed an effect 
on a several of the MCL cell lines investigated. The 
function of lenalidomide seems to require the expression 
of the wild-type form of CARD11 [38]. In support of 
this, by introducing the mutant forms of CARD11, the 
sensitive cell line Rec-1 became resistant to treatment 
by lenalidomide or the combination of lenalidomide and 
ibrutinib. A recent study also showed that intact CARD11 
is required for the activity of the pan-protein kinase C 
(PKC) inhibitor sotrastaurin in MCL lines [31]. Thus, 
mutations in CARD11, which occurred in almost 6% of 
the patients studied, would result in insensitivity to several 
of the inhibitors that are currently tested in the clinic. 
Additionally, genetic lesions in the components of the 
alternative NF-κB signaling pathway, including mutations 
in TRAF2, BIRC3 and MAP3K14 (NIK), were recently 
shown to be associated with resistance to ibrutinib [31]. 
Notably, a point mutation in MAP3K14 was identified in a 
MCL sample (P13-P), which further suggests that genetic 
characterization of the tumor genome will be important for 
the choice of therapeutic strategy for MCL patients. 
In summary, we have demonstrated that at the coding 
genome level, MCL relapse is associated with acquisition 
of new genetic lesions and in most of cases, the primary and 
relapse tumors seem to arise from a common progenitor, 
following a branched clonal evolutionary model. We 
have also identified novel mutational targets in MCL, 
exemplified by CARD11, which has important functional 
properties that provide new insights of the pathogenesis of 
MCL and may offer new therapeutic strategies.
MATERIALS AND METHODS
Patient samples
Thirteen Swedish MCL patients were included in 
the current WES study. Twenty-seven tumors (11 primary 
and 16 relapse cases) and 8 paired-normal tissue samples 
derived from these patients were analyzed (Figure 1A). 
Clinical and pathological information on all samples is 
presented in Table S1. Mutation prevalence in CARD11 
was determined in altogether 200 MCL samples from 179 
Swedish patients diagnosed between 1998 and 2013, for 
which information on age, sex, stage, cytological subtype 
and survival status were available. Genomic DNA was 
extracted from peripheral blood, frozen tumor samples, 
or viability frozen cells using DNeasy Blood & Tissue 
Kit (Qiagen, Hilden, Germany) or GenElute Mammalian 
Genomic DNA Miniprep Kit (Sigma, Taufkirchen, 
Germany), following the manufacturers’ instructions. The 
institutional review boards at Karolinska Institutet and 
Uppsala University approved the study. 
Exome sequencing and analysis pipeline
The coding genomes of tumors and respective 
non-tumor control samples were captured by Agilent’s 
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SureSelect Human All Exon Kit and libraries were 
sequenced by Illumina’s HiSeq 2000 system as described 
previously [15]. The generated sequences were aligned 
to the reference genome (hg19) using Burrows-Wheeler 
Aligner (BWA) [39]. 
Single nucleotide variants (SNVs) and insertions/
deletions (indels) were identified by Varscan2 and GATK, 
respectively [40, 41]. For the paired tumor and non-tumor 
normal samples, the latter was served as a reference for 
the detection of somatic (tumor-specific) variants and a 
paired mode was used. Somatic variants were considered 
if represented in at least 10% of the sequencing reads in the 
tumor sample and in less than 2% of sequencing reads of 
the corresponding reference sample. For primary/relapse 
tumor pairs, without corresponding non-tumor normal 
samples, the variants specific for primary or relapse tumors 
were determined using their corresponding paired-tumor 
sample as a reference, following the above criteria for the 
identification of somatic mutations. For determination of 
shared variants derived from these primary/relapse tumor 
pairs (without non-tumor controls), all SNPs annotated in 
dbSNP135 and variants with population frequency greater 
than 0.1% in the 1000 Genomes (1000g2012feb) and 
Esp6500 Exomes datasets were subtracted. Furthermore, 
variants that were not associated with previously reported, 
recurrently mutated genes in MCL and DLBCL were 
excluded [12–14, 20–24]. This may underestimate the 
number of somatic mutations in these samples, however, 
will help to avoid including of rare germline mutations. 
Population-specific frequencies of SNVs discovered by next-
generation sequencing were retrieved from 1000 Genomes 
and Esp6500 Exomes with the aid of VCFtools and Tabix 
[12, 42]. All SNVs and indels detected by bioinformatics 
analysis underwent visual inspection using IGV [43].
All mutated genes were included for pathway 
analysis with annotations performed using the KEGG 
[33] and WebGestalt tools [32]. Significance values were 
obtained from hypergeometric test (rawP) after multiple 
test adjustment [32].
After normalization of overall sequencing depths, 
DNA copy-number variations (CNVs) were called 
in tumors with reference to matched controls using 
ExomeCNV [44] and annotated by GISTIC2.0 to identify 
significant regions of amplification and deletion [45].
Sanger sequencing
The coding regions of CC domain of CARD11 were 
analyzed in altogether 179 MCL samples (including 6 samples 
that have been sequenced by WES) by Sanger sequencing. 
In addition, 29 mutations in other genes, identified by WES, 
were chosen for validation by Sanger sequencing and all 
alterations could be confirmed (Table S3B–S3C). PCR 
and sequencing primers were designed with NCBI/Primer-
BLAST [46] and primer sequences are available upon 
request. The resulting PCR products were purified by using 
the Qiaquick PCR purification kit (Qiagen, Hilden, Germany) 
and sequenced at Macrogen Inc. (Seoul, Korea) or Eurofins 
MWG Operon (Ebersberg, Germany).
Preparation of recombinant adenoviruses
AdEasy Adenoviral Vector System kit (Stratagene, 
Waldbronn, Germany) was used to prepare recombinant 
adenoviruses containing cDNA of wild-type or four 
CARD11 mutants (G123S, D230N, D357E and Y361C) 
by homologous recombination [47]. Briefly, cDNA of 
wild-type or mutant CARD11 was subcloned into pShuttle-
CMV vector provided in the kit. The resulting plasmid 
was co-transformed with adenoviral backbone plasmid 
(pAdEasy-1) into E. coli BJ5183 cells. Recombinant 
adenoviruses were produced in HEK293 cells. The 
expression of GFP (AdGFP) was used as a marker 
for monitoring infection efficiency by calculating the 
percentage of GFP positive cells with a Zeiss Primovert 
microscope. The expression of different CARD11 
constructs was furthermore confirmed by western blot. 
Cell proliferation assay
Six MCL cell lines (Granta519, Jeko-1, Z-138, 
Rec- 1, Mino and JVM2) were included in the cell 
proliferation assay and were also analyzed by WES 
(Table S2). Cells were plated at a density of 8000 cells 
per well in 96-well plates. For overexpression of wild-
type or mutant forms of CARD11, three MCL cell lines 
(Granta519, JVM2 and Rec-1) were infected with 
recombinant adenoviruses during cell plating and were 
incubated in a cell culture incubator at 37°C for 48 hours 
before the drug treatment. For each well, lenalidomide 
(0–4 µM, CC-5013, Selleckchem, Munich, Germany) 
and/or ibrutinib (0–1 nM, PCI-32765, Selleckchem) were 
added (final volume 200 ml). After 4 days of treatment, 
cell viability was evaluated by CellTiter 96® AQueous one 
solution cell proliferation assay (Promega, Madison, USA) 
according to the manufacturer’s instructions. Background 
absorbance was subtracted using a medium-only control.
IGHV-IGHD-IGHJ rearrangements
To determine whether the primary and relapse 
samples derived from the same patient were clonally 
related, rearranged IGHV-IGHD-IGHJ genes were 
amplified from the tumor DNA samples as described 
previously [48]. IGHV gene usage, somatic mutations in 
the IGVH genes, length and composition of the CDR3 
regions were analyzed by the IMGT/V-QUEST tools [49].
Statistical analysis
Fisher’s exact test or c2 test was used for group 
comparisons. The Wilcoxon signed-rank test was used 
Oncotarget38188www.impactjournals.com/oncotarget
for the comparison of somatic mutation pattern between 
primary and relapse tumors from individual patient. 
Overall survival was measured from date of diagnosis to 
date of death or last follow-up. A p value of < 0.05 was 
considered statistically significant.
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